Antipsychotic Use: Cross-Sectional Opinion Survey of Psychiatrists in India and United Kingdom

The aim of this survey of psychiatrists from the UK and India was to compare their opinions on antipsychotic medication choice and their experiences of such medications’ effectiveness and tolerability in patients who were newly diagnosed with acute schizophrenia. Following ethical approval, a cross-...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacy 2023-10, Vol.11 (5), p.162
Main Authors: Qadir, Zina Sherzad, Kar, Nilamadhab, Ball, Patrick Anthony, Morrissey, Hana
Format: Article
Language:English
Subjects:
Antipsychotic drugs
antipsychotics
antipsychotics discontinuation rate
causes of relapse
Dopamine
Drug therapy
Health services
Mental health
Minority & ethnic groups
optimisation of schizophrenia management
Patients
psychiatric disorders
Psychiatrists
Psychological aspects
Psychosis
Questionnaires
Schizophrenia
Social networks
Statistical analysis
Surveys
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this survey of psychiatrists from the UK and India was to compare their opinions on antipsychotic medication choice and their experiences of such medications’ effectiveness and tolerability in patients who were newly diagnosed with acute schizophrenia. Following ethical approval, a cross-sectional online survey of psychiatrists from the UK and India was conducted. Ninety-five responses were received from each country. The most selected first-line APDs in both countries were olanzapine (47.5%), risperidone (42.8%) and aripiprazole (25.3%). A total of 60% of psychiatrists from India (60%) and 48% from the UK (48%) selected ‘medication efficacy’ as the main factor in their choice. Reassessment and consideration to switch most often took place within 4–6 weeks (53.7%) and 3–6 months (11.6%). The major reasons for switching antipsychotic medications were poor clinical efficacy (69%) and lack of tolerability (45%). Nonadherence was the most common reason for relapse (90% of UK psychiatrists and 70% of Indian psychiatrists), followed by illicit drug use (27.6%). The most commonly reported side effects that led to nonadherence were weight gain (10.8%), drowsiness (10.4%), erectile dysfunction and movement disorders (equally 8.7%). It was concluded that olanzapine, risperidone and aripiprazole are the most commonly selected as the initial treatment choice by psychiatrists from India and the UK. They are perceived as widely effective and well tolerated.
ISSN:2226-4787
2226-4787
DOI:10.3390/pharmacy11050162